Zacks Investment Research
06 Aug 2026, 15:51 UTC · 1h ago
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Aug 2026, 15:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Medpace reported record second-quarter net new business awards of $795.7 million, a 28.2% increase year-over-year. — Strong growth in new business awards is a leading indicator of future revenue growth and market share gains.
+0.60Medpace's ending backlog reached $3.01 billion, with $1.96 billion expected to convert over the next 12 months. — High backlog provides significant revenue visibility and reduces short-term downside risk.
+0.50Zacks Consensus Estimates forecast 2026 sales growth of 12.4% and earnings growth of 14.6% for Medpace. — Positive double-digit growth projections support a bullish outlook for the stock's trajectory.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Medpace maintains a strong balance sheet with $502.7 million in cash, zero debt, and $527 million remaining in share repurchase authorization. — Strong liquidity and buyback capacity provide a floor for the stock price and financial flexibility.
Medpace trades at 31.8X forward 12-month earnings, which is described as far above industry and market levels. — A high valuation premium increases the risk of a price correction if growth fails to meet expectations.
-0.30Which stocks this story touches
The company shows double-digit earnings growth, record new business awards, and resilient profitability.
Mentioned as a larger peer in the industry without a specific positive or negative catalyst.
Mentioned as a larger peer in the industry without a specific positive or negative catalyst.
[mutual] IQVIA and ICON plc are described as larger peers in the contract research market.
[mutual] Medpace and IQVIA are identified as peers in the contract research market.
[mutual] Medpace and ICON plc are identified as peers in the contract research market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
